Herpes simplex virus (HSV), the first virotherapy to be approved by the FDA, has low pathogenicity but required extensive genetic modification to preferentially target cancer cells and to enhance immunogenicity (e.g., incorporation of a GM-CSF transgene).33 This evidence concerns the gene CSF2 and cancer.